- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Chemical Biology
- ACRF Stem Cells and Cancer
- Bioinformatics
- Cancer and Haematology
- Cell Signalling and Cell Death
- Development and Cancer
- Immunology
- Infection and Immunity
- Inflammation
- Molecular Genetics of Cancer
- Molecular Immunology
- Molecular Medicine
- Population Health and Immunity
- Structural Biology
- Systems Biology and Personalised Medicine
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- Opportunities in platform technologies
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Fut8 Sugar coating immuno oncology
- Intercepting inflammation with RIPK2 inhibitors
- Novel checkpoints NK cells emerge as key players in IO
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting plasmacytoid dendritic cells for systemic lupus erythematosus
- Treating Epstein-Barr virus associated malignancies
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Research fields
- Bioinformatics
- Cancer biology
- Cell death
- Cell signalling
- Clinical translation
- Computational biology
- Drug discovery
- Epigenetics
- Flow cytometry
- Genomics
- Haematology
- Imaging
- Immunology
- Infection
- Inflammation
- Medicinal chemistry
- Personalised medicine
- Proteomics
- Stem cells
- Structural biology
- Systems biology
- Vaccine development
- People
- Anne-Laure Puaux
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Anne Voss
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Edwin Hawkins
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marnie Blewitt
- Associate Professor Matthew Ritchie
- Associate Professor Mike Lawrence
- Associate Professor Nicholas Huntington
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bob Anderson
- Dr Brad Sleebs
- Dr David Komander
- Dr Diana Hansen
- Dr Drew Berry
- Dr Emma Josefsson
- Dr Ethan Goddard-Borger
- Dr Gary Pitt
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Hélène Jousset Sabroux
- Dr Ian Majewski
- Dr Ian Street
- Dr Jacqui Gulbis
- Dr James Vince
- Dr Jason Tye-Din
- Dr Joanna Groom
- Dr John Wentworth
- Dr Julie Mercer
- Dr Kate Sutherland
- Dr Kelly Rogers
- Dr Ken Pang
- Dr Leanne Robinson
- Dr Leigh Coultas
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Marie-Liesse Asselin-Labat
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Melissa Davis
- Dr Michael Low
- Dr Misty Jenkins
- Dr Peter Czabotar
- Dr Philippe Bouillet
- Dr Priscilla Auyeung
- Dr Rhys Allan
- Dr Ruth Kluck
- Dr Samar Ojaimi
- Dr Samir Taoudi
- Dr Sant-Rayn Pasricha
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Stan Balbata
- Mr Steve Droste
- Ms Carolyn MacDonald
- Ms Samantha Ludolf
- Ms Wendy Hertan
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Clare Scott
- Professor David Huang
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Li Wu
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Melanie Bahlo
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- 3D and 4D imaging of thymic T cell differentiation
- Activating https://www.wehi.edu.au/node/add/individual-student-research-page#Parkin to treat Parkinson’s disease
- Activation, regulation, and biological roles of E3 ubiquitin ligases
- Bioinformatics methods for detecting and making sense of somatic genomic rearrangements
- Characterising regulatory T cells in coeliac disease
- Computational melanoma genomics
- Deep profiling of blood cancers during targeted therapy
- Defining the role of necroptosis in platelet production and function
- Determining the migration signals leading to protective immune responses
- Developing mucolytics to treat chronic respiratory diseases
- Developing new tools to visualise necroptotic cell death
- Development of live-cell, automated microscopy techniques for studying malaria
- Development of tools to inform malaria vaccine design
- Discovering new genetic causes of primary antibody deficiencies
- Discovery of novel drug combinations for the treatment of bowel cancer
- Dissecting the induction and integration of T cell migration cues
- Drug targets and compounds that block growth of malaria parasites
- Effects of nutrition on immunity and infection in Asia and Africa
- Eosinophil and neutrophil heterogeneity
- Eosinophil maturation
- Epigenetic regulation of systemic iron homeostasis
- Functional differences between young and old platelets
- Generation of cytokine antagonists
- Genetic dissection of mechanisms of Plasmodium invasion
- Genomic characterisation of epigenetic regulators involved in X inactivation
- High resolution 3-dimensional imaging to characterise metastatic cancers
- High-resolution imaging of host cell invasion by the malaria parasite
- Home renovations: understanding how Toxoplasma redecorates its host cell
- How the epigenetic regulator SMCHD1 works and how to target it to treat disease
- Human monoclonal antibodies against malaria infection
- Identification of malaria parasite entry receptors
- Identification of new therapeutic opportunities for pancreatic cancer
- Identifying disease-causing haplotypes with hidden Markov models
- Interleukin-11 in gastrointestinal bacterial infections
- Investigating mechanisms of cell death and survival using zebrafish
- Investigating new paths to selective modulation of potassium channels
- Let me in! How Toxoplasma invades human cells
- Long-read sequencing for transcriptome and epigenome analysis
- Macro-evolution in cancer
- Mapping DNA repair networks in cancer
- Mapping how multiple malaria episodes are related
- Modelling gene regulatory systems
- Modulation of immune responses by immunosuppressive chemokines
- Molecular basis for inherited Parkinson’s disease mechanism of PINK1
- Mucus at the molecular level
- Novel cell death and inflammatory modulators in lupus
- Plasmodium vivax host-parasite interactions: impact on immunity
- Predicting drug response in cancer
- Programming T cells to defend against infections
- Reconstructing the immune response: from molecules to cells to systems
- Regulation of cytokine signalling
- Screening for regulators of jumping genes
- Target identification of potent antimalarial agents
- Targeting the immune system in cancer
- The role of interleukin-11 in acute myeloid leukaemia
- Transmembrane control of type I cytokine receptor activation
- Uncovering the roles of long non-coding RNAs in human bowel cancer
- Understanding retinal eye diseases with retinal transcriptomic data analysis
- Understanding the role of stromal cells in pancreatic cancer growth
- Unravelling the tumour suppressor network in models of lung cancer
- Utilising pre-clinical models to discover novel therapies for tuberculosis
- Zombieland: evolution of a dead enzyme that kills cells by necroptosis
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Casey Ah-Cann
- Catia Pierotti
- Charlotte Slade
- Daniel Cameron
- Emma Nolan
- Jason Brouwer
- Joy Liu
- Lucille Rankin
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Sarah Garner
- Simona Seizova
- Michael Low
- Sofonias Tessema
- Santini Subramaniam
- Miles Horton
- Alexandra Gurzau
- Tamara Marcus
- Nicholas Chandler
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Inflammation

Inflammation is an early defense that protects our body from infection. However, ongoing or misdirected inflammation underlies many diseases.
Our researchers are revealing how inflammation is controlled, and advancing the diagnosis and treatment of inflammatory diseases.
Our inflammation research
Our researchers seek to understand how inflammation is controlled in health and disease. To do this they are investigating:
- The molecules and cells that contribute to the initiation, magnitude and resolution of inflammatory responses.
- Inflammatory pathways that are associated with disease.
- New strategies to treat harmful inflammation, and promote beneficial inflammation.
The goal of our inflammation research is to advance strategies to diagnose, treat and prevent inflammatory diseases including:
- Coeliac disease
- Inflammatory bowel disease
- Lupus
- Multiple sclerosis
- Rheumatic fever
- Rheumatoid arthritis
- Type 1 diabetes
- Infections including influenza and malaria
- Cancers associated with inflammation such as bowel cancer and stomach cancer
What is inflammation
Inflammation is the body’s natural response to infection, disease and tissue damage. Inflammation is driven by immune cells, and also serves to heighten the immune response.
Features of inflamed tissues include:
- Redness and warmth, from increased blood flow to the area.
- Swelling, from an influx of fluid.
- Pain.
- Immobility.
These symptoms of inflammation serve several important functions:
- Alerting and attracting immune cells to an area of potential infection.
- Releasing substances that help to repair damaged tissue.
- Immobilising the injured or infected tissue to reduce damage or spread of infection.
Inflammation can be acute, meaning it is rapidly resolved, or chronic, meaning it can persist for years.
What causes inflammation?
Inflammation can have a variety of triggers including:
- Tissue damage, such as a burn or cut.
- Clot formation by platelets.
- The presence of a foreign substance.
- Microbial infection.
- Some forms of cell death.
Inflammation begins with innate immune cells, such as neutrophils, being alerted to the trigger. This may be because damaged tissue has released ‘alert’ signals, or because the immune cell has detected microbial molecules such as bacterial cell wall components.
When activated, innate immune cells can immediately release a variety of inflammatory substances. These substances trigger the features of inflammation in nearby tissue, protecting the site and attracting an influx of additional immune cells. Different immune cell types, and inflammatory mediators are detected in acute and chronic inflammation.
Inflammatory mediators are typically short-lived. This serves to limit the duration of an inflammatory response. As soon as the trigger is removed, inflammation will normally diminish, preventing tissue damage.
Inflammation and cell death
Our research into how cells die has revealed that many of the molecules contributing to cell death have dual roles in inflammation, or are closely related to molecules functioning in inflammatory pathways.
Some types of cell death trigger inflammation. This ensures that the abnormal death of cells alerts immune cells to a potentially dangerous situation.
Beneficial inflammation
Inflammation is an important component of the innate immune response, which is the body’s first line of defense against infection. Inflammatory mediators enhance the responses of immune cells to potential infections, by:
- Increasing blood flow and movement of immune cells into the inflamed tissue
- Stimulating immune cells, such as triggering macrophages to be more likely to engulf nearby substances.
- Stimulating production of new immune cells through the release of colony stimulating factors
Inflammation is important for the generation of protective immunological memory. This ensures that repeat exposures to a microbe are rapidly dealt with by established immune cells that recognise the infectious agent.
Most vaccines include substances that trigger inflammation. These contribute to better immune responses, and longer-lasting immune protection.
Inflammatory diseases
Excessive or ongoing inflammation can cause pain and tissue damage, and prevent the normal functioning of the body’s organs.
Short-term, acute inflammation can be responsible for many of the symptoms of infections. These symptoms, such as fever, tend to assist the immune clearance of infection. Excessive or misplaced acute inflammation can cause severe illness or death.
Chronic inflammation is also associated with many diseases. Approximately one in three Australians has a chronic inflammatory disease, such as rheumatoid arthritis. These diseases place a significant social and economic burden on the community.
Chronic inflammation is triggered by ongoing immune responses. These immune responses can be against:
- A chronic infection that is not cleared. Chronic inflammation to the hepatitis B virus contributes to liver damage.
- The body’s own tissue, such as joint tissue in rheumatoid arthritis.
In some conditions, such as rheumatic fever, inflammation begins in response to an infection by Streptococcus bacteria, but is redirected later to heart tissue, causing damage.
Treating inflammation
In many inflammatory diseases, symptoms can be greatly reduced in the short term by appropriate treatment. These include:
- Corticosteroids that reduce immune cell function.
- ‘Non-steroidal’ anti-inflammatory medications that interfere with key molecules or cells contributing to the symptoms of inflammation.
- Targeted therapies that specifically inhibit the molecules that underpin inflammation or immune cell function. These are showing great promise in improving the outlook for people with inflammatory diseases.
Compressing, immobilising and cooling the inflamed area can also improve the symptoms of inflammation, but do not eliminate the underlying cause of the inflammation.
Researchers:
WEHI.TV animation: how insulin is normally produced in the body and how its production is destroyed in type 1 diabetes.
Dr Tracy Putoczki presents her research findings into targeting cytokines in inflammatory diseases with a focus on Interkeukin-11.
Our research has revealed the structure of a protein that triggers a form of programmed cell death called necroptosis
Our public forum explained how research into arthritis is leading to better treatments.
While most proteins were readily consumed, some people’s immune systems struggled to tolerate others.